Details of the Drug Reposition

General Information of This Drug (ID: DMMX2E6)

• Drug Name: Pemetrexed (DMMX2E6)
• Synonyms: Alimta; LYA; LY 231514; LY231514; Alimta (TN); LY 231,514; LY-2315; LY-231514; Pemetrexed (INN); Pemetrexed [INN:BAN]; LY-231,514; N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid; N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-d-glutamic acid; (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; (2S)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid; 2-{4-[2-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-5-YL)-ETHYL]-BENZOYLAMINO}-PENTANEDIOIC ACID
• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

Information on Drug Reposition of This Drug

4 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Sarcomatoid mesothelioma	DISCCHZN	N.A.	Approved	[1]
Central nervous system lymphoma	DISBYQTA	2B33.5	Approved	[1]
Small-cell lung cancer	DISK3LZD	2C25.Y	Approved	[1]
Epithelioid mesothelioma	DIS17SNY	2F10	Approved	[1]

2 Discontinued in Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Neoplasm of esophagus	DISOLKAQ	N.A.	Discontinued in Phase 2	[2]
Malignant pleural mesothelioma	DIST2R60	2C26.0	Discontinued in Phase 2	[3]

1 Investigative Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Lung neoplasm	DISVARNB	N.A.	Investigative	[1]

References

• [1] Pemetrexed FDA Label
• [2] Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
• [3] Capecitabine, Oxaliplatin, and Gefitinib in Treating Patients With Metastatic Colorectal Cancer